Navigation Links
Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Date:4/2/2009

and technical issues; clinical trials, including the DURATION-2 clinical trial mentioned in this press release, not being completed in a timely manner, not confirming previous results, or not achieving the intended clinical endpoints; pre-clinical trials not predicting future results; label expansion requests or New Drug Application ("NDA") filings, including the NDA filing for exenatide once weekly, not being submitted in a timely manner; regulatory approval being delayed or not received; or manufacturing and supply issues. The potential for BYETTA, SYMLIN and/or exenatide once weekly may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products. These risks also include a potential adverse impact on our financial condition if the steps outlined in this press release to address the change of control provisions in two of our debt agreements are unsuccessful and we are required to repay the amounts outstanding under any of our debt agreements. These and additional risks and uncertainties are described more fully in Amylin's most recent SEC filings including its Annual Report on Form 10-K. Amylin undertakes no duty to update these forward-looking statements.

Additional Information and Where to Find It

This release may be deemed to be solicitation material in respect of the matters to be considered at the 2009 Annual Meeting of Stockholders. Amylin will be filing a proxy statement with the Securities and Exchange Commission ("SEC"). INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT, THE BLUE PROXY CARD AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and securityholders will be able to receive the proxy statement and other re
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Senior supply chain management executives from over 50 ... of “Reducing Cost, Lead Time, & Defects in the ... the partnership of the Bio Supply Management Alliance ( ... SCMI) of the University of San Diego in ... Institute of Peace and Justice in San Diego, Devendra ...
(Date:7/10/2014)... , July 10, 2014 On ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique project ... project BIOCAD develops a number of innovative drugs based ... diseases. The ceremony took place at the International Exhibition ...
(Date:7/10/2014)... July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, ... today announced an agreement with Lineagen, Inc., ... Lineagen,s NextStep Dx PLUS.  Lineagen, focused ... neurological disorders, currently offers FirstStep Dx ... service used by healthcare providers as a ...
(Date:7/10/2014)... Calif., July 10, 2014   Ceres, Inc . ... seed company, announced today financial results for the three ... on its business. Ceres reported that the ... product performance this growing season in Brazil, which concluded ... the company,s sorghum evaluation areas for part of the ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... in Nature Physics , they used graphene, the world,s ... Graphene is a sheet of carbon atoms arranged in a ... signs of the conventional magnetism usually associated with such materials ... Manchester researchers the Nobel Prize in Physics in 2010. ...
... LONDON, January 6, 2012 The Lancet ... its first app for iPad is now available on the ... app that makes it easier for healthcare professionals (HCPs) to find ... their iPad. , ,"In this new mobile and tablet age, ...
... company developing a revolutionary non-invasive test for the early ... that it has achieved full automation of its Cell-CT™ ... biosignatures from intact cells.  Development of the fully automated ... $2.6 million grant from the National Institutes of Health,s ...
Cached Biology Technology:Graphene reveals its magnetic personality 2The Lancet Makes Research More Accessible for Healthcare Professionals With New App for iPad 2VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer 2VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer 3VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer 4
(Date:7/11/2014)... In addition to the hippocampus, the marginal division ... and memory. What is the impact degree of ... learning and memory function? Yan Yu and his ... China found, using immunofluorescence staining, that substance P ... hippocampus and striatal marginal division of normal rats. ...
(Date:7/11/2014)... let nerve cells send out electrical signals, Johns Hopkins ... that may offer a new way to protect crops ... way. , Their findingthat naturally occurring insect toxins ... a closely related onesuggests that insecticides can be designed ... bees. A summary of the research, led by Frank ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... the Entomological Society of America (ESA) features the Linnaean ... a lively question-and-answer, college bowl-style competition on insect facts ... and entertaining component of the ESA Annual Meeting. ... Branches will compete in the national competition this December ...
... Largo, Fla. April 27, 2009 A new study ... for reattaching large sponges that have been dislodged from coral ... of other large sponge species removed by human activities or ... sponge were removed and reattached at Conch Reef off of ...
... 27, 2009) In an in vitro study, led by ... discovered how a protein called SUMO (Small Ubiquitin-related Modifier) ... chromatin to regulate expression of genes. Chromatin is a ... chromosomes. The interaction between SUMO and the enzyme complex ...
Cached Biology News:Entomological Society of America's Linnaean Games teams selected 2Large sponges may be reattached to coral reefs 2SUMO protein guides chromatin remodeler to suppress genes 2
...
... XL provides RS232/Serial data collection and automation ... Complete instrument integration with Microsoft Excel ... balances, pH meters, titrators, density meters, force ... and serial instruments can be added and ...
DNA sequencing - plasmids or PCR fragments, 3-7 working days service....
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Biology Products: